Observational studyRMD open2020
Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study.
Observational study in RMD open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03835780 (The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a UK Matched Cohort Study
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Trial
- Trial
- Exploring the risk of venous thromboembolism in women with rheumatoid arthritis initiating menopausal hormone treatment in England.Rheumatology advances in practice · 2026Article
- Risk of venous thromboembolism in people with RA: a population-based study in the UK.Rheumatology (Oxford, England) · 2025Article
- VTE risk assessment and management in admitted patients at a private hospital in Dubai- A quality improvement project.BMC health services research · 2025Article
- Risk of venous thromboembolism in patients with rheumatoid arthritis: a meta-analysis of observational studies.BMC rheumatology · 2024Article
- Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease-results from the nationwide Norwegian Cardio-rheuma registry.European heart journal. Cardiovascular pharmacotherapy · 2024Article
- Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?Gastroenterology & hepatology · 2023Article
- MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.RMD open · 2023Article
- Venous Thromboembolism After COVID-19 Infection Among People With and Without Immune-Mediated Inflammatory Diseases.JAMA network open · 2023Article
- The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2023Article
- Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.Advances in therapy · 2023Article
- High systemic inflammation response index level is associated with an increased risk of lower extremity deep venous thrombosis: a large retrospective study.Annals of medicine · 2023Article
- Article
- A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.Rheumatology (Oxford, England) · 2022Review
- Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors.Open access rheumatology : research and reviews · 2022Review
- Immune-mediated inflammatory diseases and risk of venous thromboembolism: A Mendelian randomization study.Frontiers in immunology · 2022Article
- International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo describe the risk of venous thromboembolism (VTE), and risk factors for VTE, in people with immune-mediated inflammatory diseases (IMID) (ulcerative colitis, Crohn's disease (CD), rheumatoid arthritis (RA) and psoriatic arthritis (PsA)), compared with a matched control population.
methodsA total of 53 378 people with an IMID were identified over 1999-2019 in the UK Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) primary care database and were matched to 213 512 people without an IMID. The association between the presence of any IMID, and each IMID separately, and risk of VTE was estimated using unadjusted and multivariable-adjusted Cox proportional hazards models. The prevalence of VTE risk factors, and associations between VTE risk factors and risk of VTE, were estimated in people with and without an IMID.
resultsPeople with an IMID were at increased risk of VTE (adjusted HR [aHR] 1.46, 95% CI 1.36,1.56), compared with matched controls. When assessing individual diseases, risk was increased for CD (aHR 1.74, 95% CI 1.45 to 2.08), ulcerative colitis (aHR 1.27, 95% CI 1.10 to 1.45) and RA (aHR 1.54, 95% CI 1.40 to 1.70) but there was no evidence of an association for PsA (aHR 1.21, 95% CI 0.96 to 1.52). In people with an IMID, independent risk factors for VTE included male sex, overweight/obese body mass index, current smoking, history of fracture, and, across study follow-up, abnormal platelet count.
conclusionsVTE risk is increased in people with IMIDs. Routinely available clinical information may be helpful to identify individuals with an IMID at increased future risk of VTE. OBSERVATIONAL STUDY REGISTRATION NUMBER: Clinicaltrials.gov (NCT03835780).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.